Status:
COMPLETED
Sevoflurane In Acute Myocardial Infarction
Lead Sponsor:
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Ischemic postconditioning can reduce myocardial injury following myocardial infarction. A potential pharmacological agent is the anesthetic Sevoflurane. The investigators' hypothesis is that sevoflur...
Detailed Description
Patients with first STEMI that will be treated by primary PCI, will be randomized to sedation with Sevoflurane during the procedure or to usual care.
Eligibility Criteria
Inclusion
- First STEMI, presenting within 6 hours after the onset of chest pain
- Symptoms lasting \> 30 minutes
- Persistent ST-segment elevation \> 0.1 mV in 2 or more contiguous leads
Exclusion
- Hypersensitivity to sevoflurane or other halogenated agents
- Malignant hyperthermia
- Cardiac arrest
- Cardiogenic shock
- Previous myocardial infarction or coronary bypass surgery
- Pre-infarction angina
- Heart failure (NYHA III/IV)
- Chronic inflammatory disease
- Severe renal impairment
- Hepatic dysfunction
- Use of Glyburide
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00971607
Start Date
May 1 2009
End Date
December 1 2013
Last Update
September 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London Health Sceinces Centre
London, Ontario, Canada, N6A5A5